{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:18:45Z","timestamp":1790014725814,"version":"4.0.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007331","name":"Aichi Kidney Foundation","doi-asserted-by":"publisher","award":["2020-7"],"award-info":[{"award-number":["2020-7"]}],"id":[{"id":"10.13039\/501100007331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Mycophenolate mofetil (MMF), a prodrug of the immunosuppressive agent mycophenolic acid (MPA), is difficult to administer because of the pharmacokinetic complexity of MPA. Although dosage adjustment according to the 12-h area under the concentration\u2013time curve (AUC<jats:sub>0-12<\/jats:sub>) is thought to be desirable, multiple blood samplings for AUC calculation may pose a clinical challenge. A limited sampling strategy (LSS) would provide a solution; however, little is known about MPA pharmacokinetics in lupus nephritis patients, especially in those with Asian backgrounds, or few, if any, LSSs are reported for them.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Thirty-four adult Japanese patients receiving MMF for lupus nephritis were examined retrospectively. MPA pharmacokinetics were investigated, and a PPK model was developed using Phoenix\u00ae NLME\u2122 software. Single and double blood sampling strategies from Bayesian estimation using the PPK model and from multiple linear regression were compared. Tolerability was also evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the pharmacokinetic analysis, renal function and serum albumin had significant effects on dose-normalized AUC<jats:sub>0-12<\/jats:sub>; and serum albumin, concomitant proton pump inhibitor (PPI) and iron\/magnesium oxide did on dose-normalized maximum concentration. As a PPK model, a two-compartment model was developed with a transit absorption model and first-order elimination, in which creatinine clearance and serum albumin were covariates for MPA clearance. The double sampling strategy at 1 and 4\u00a0h by multiple linear regression showed the best agreement with the observed AUC<jats:sub>0-12<\/jats:sub> (<jats:italic>r<\/jats:italic><jats:sup><jats:italic>2<\/jats:italic><\/jats:sup>\u2009=\u20090.885). Of the single sampling strategies, the one at 6\u00a0h by Bayesian estimation performed best (<jats:italic>r<\/jats:italic><jats:sup><jats:italic>2<\/jats:italic><\/jats:sup>\u2009=\u20090.769). The tolerability evaluation showed that correlations were suggested for gastrointestinal involvement.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The present study developed the first PPK model of MPA for Japanese lupus nephritis patients. As for LSSs, a double sampling strategy at 1 and 4\u00a0h by multiple linear regression would work best; when only a single blood sampling is allowed, a strategy at 6\u00a0h by Bayesian estimation using the PPK model developed in this study would be best. The LSSs good enough for clinical use may facilitate safer, more effective, and individualized therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40780-022-00271-w","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T14:04:27Z","timestamp":1673273067000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of mycophenolate mofetil in Japanese patients with lupus nephritis"],"prefix":"10.1186","volume":"9","author":[{"given":"Tomoko","family":"Mizaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Nobata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Banno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kinashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Iwagaitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Ishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Kuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Sako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9676-6961","authenticated-orcid":false,"given":"Yasuhiko","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"271_CR1","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","volume":"79","author":"A Fanouriakis","year":"2020","unstructured":"Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79:713\u201323.","journal-title":"Ann Rheum Dis"},{"key":"271_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","volume":"47","author":"AC Allison","year":"2020","unstructured":"Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2020;47:85\u2013118.","journal-title":"Immunopharmacology"},{"key":"271_CR3","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/sj.bjp.0702399","volume":"12","author":"M Shipkova","year":"1999","unstructured":"Shipkova M, Armstrong VW, Wieland E, Niedmann PD, Schutz E, Brenner-Weiss G, et al. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol. 1999;12:1075\u201382.","journal-title":"Br J Pharmacol"},{"key":"271_CR4","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2165\/00003088-199834060-00002","volume":"34","author":"RE Bullingham","year":"1998","unstructured":"Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429\u201355.","journal-title":"Clin Pharmacokinet"},{"key":"271_CR5","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1248\/bpb.34.755","volume":"34","author":"Y Mino","year":"2011","unstructured":"Mino Y, Naito T, Shimoyama K, Ogawa N, Kawakami J. Pharmacokinetic variability of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in remission maintenance phase. Biol Pharm Bull. 2011;34:755\u20139.","journal-title":"Biol Pharm Bull"},{"key":"271_CR6","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10928-009-9136-6","volume":"36","author":"BC de Winter","year":"2009","unstructured":"de Winter BC, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA. Limited sampling strategies for therapeutic drug monitoring of mycophenolate mofetil therapy in patients with autoimmune disease. J Pharmacokinet Pharmacodyn. 2009;36:541\u201364.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"271_CR7","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1093\/rheumatology\/keq238","volume":"49","author":"M Schaier","year":"2010","unstructured":"Schaier M, Scholl C, Scharpf D, Hug F, Bonisch-Schmidt S, Dikow R, et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. Rheumatology. 2010;49:2061\u20137.","journal-title":"Rheumatology"},{"key":"271_CR8","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s002280000227","volume":"56","author":"M Vietri","year":"2000","unstructured":"Vietri M, Pietrabissa A, Mosca F, Pacifici GM. Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. Eur J Clin Pharmacol. 2000;56:659\u201364.","journal-title":"Eur J Clin Pharmacol"},{"key":"271_CR9","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1046\/j.1523-1755.2002.00531.x","volume":"62","author":"D Cattaneo","year":"2002","unstructured":"Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002;62:1060\u20137.","journal-title":"Kidney Int"},{"key":"271_CR10","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1177\/0961203320931567","volume":"29","author":"M Romano-Aguilar","year":"2020","unstructured":"Romano-Aguilar M, Resendiz-Galvan JE, Medellin-Garibay SE, Milan-Segovia RDC, Martinez-Martinez MU, Abud-Mendoza C, et al. Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis. Lupus. 2020;29:1067\u201377.","journal-title":"Lupus"},{"key":"271_CR11","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/tri.12382","volume":"27","author":"P Li","year":"2014","unstructured":"Li P, Shuker N, Hesselink DA, van Schaik RH, Zhang X, van Gelder T. Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients? Transpl Int. 2014;27:994\u20131004.","journal-title":"Transpl Int"},{"key":"271_CR12","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa043731","volume":"353","author":"EM Ginzler","year":"2005","unstructured":"Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353:2219\u201328.","journal-title":"N Engl J Med"},{"issue":"R182","key":"271_CR13","first-page":"1","volume":"8","author":"RA Moore","year":"2006","unstructured":"Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther. 2006;8(R182):1\u201310.","journal-title":"Arthritis Res Ther"},{"key":"271_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/8630596","volume":"8630596","author":"Y Abe","year":"2021","unstructured":"Abe Y, Tada K, Yamaji K, Tamura N. Real-World Experience of Safety of Mycophenolate Mofetil in 119 Japanese Patients with Systemic Lupus Erythematosus: A Retrospective Single-Center Study. Biomed Res Int. 2021;8630596:1\u20137.","journal-title":"Biomed Res Int"},{"key":"271_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4103\/0971-5916.93429","volume":"135","author":"SC Sarangi","year":"2012","unstructured":"Sarangi SC, Reeta KH, Agarwal SK, Kaleekal T, Guleria S, Gupta YK. A pilot study on area under curve of mycophenolic acid as a guide for its optimal use in renal transplant recipients. Indian J Med Res. 2012;135:84\u201391.","journal-title":"Indian J Med Res"},{"key":"271_CR16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/ki.2010.170","volume":"78","author":"P Lertdumrongluk","year":"2010","unstructured":"Lertdumrongluk P, Somparn P, Kittanamongkolchai W, Traitanon O, Vadcharavivad S, Avihingsanon Y. Pharmacokinetics of mycophenolic acid in severe lupus nephritis. Kidney Int. 2010;78:389\u201395.","journal-title":"Kidney Int"},{"key":"271_CR17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.12659\/AOT.894954","volume":"20","author":"J Zegarska","year":"2015","unstructured":"Zegarska J, Hryniewiecka E, Zochowska D, Tszyrsznic W, Jazwiec R, Borowiec A, et al. Mycophenolic Acid Metabolites Acyl-Glucuronide and Glucoside Affect the Occurrence of Infectious Complications and Bone Marrow Dysfunction in Liver Transplant Recipients. Ann Transplant. 2015;20:483\u201392.","journal-title":"Ann Transplant"},{"key":"271_CR18","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1248\/bpb.29.2099","volume":"29","author":"N Sugioka","year":"2006","unstructured":"Sugioka N, Sasaki T, Kokuhu T, Ito Y, Shibata N, Okamoto M, et al. Clinical pharmacokinetics of mycophenolate mofetil in Japanese renal transplant recipients: A retrospective cohort study in a single center. Biol Pharm Bull. 2006;29:2099\u2013105.","journal-title":"Biol Pharm Bull"},{"key":"271_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.trre.2010.06.001","volume":"25","author":"SE Tett","year":"2011","unstructured":"Tett SE, Saint-Marcoux F, Staatz CE, Brunet M, Vinks AA, Miura M, et al. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplant Rev. 2011;25:47\u201357.","journal-title":"Transplant Rev"},{"key":"271_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2215\/CJN.07111009","volume":"5","author":"DR Kuypers","year":"2010","unstructured":"Kuypers DR, Le Meur Y, Cantarovich M, Tredger MJ, Tett SE, Cattaneo D, et al. Transplantation Society (TTS) Consensus Group on TDM of MPA. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol. 2010;5:341\u201358.","journal-title":"Clin J Am Soc Nephrol"},{"key":"271_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/TP.0b013e3181e06584","volume":"90","author":"KA Barraclough","year":"2010","unstructured":"Barraclough KA, Isbel NM, Staatz CE. Evaluation of the mycophenolic acid exposure estimation methods used in the APOMYGERE, FDCC, and Opticept trials. Transplantation. 2010;90:44\u201351.","journal-title":"Transplantation"},{"key":"271_CR22","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1097\/TP.0b013e318186f98a","volume":"86","author":"T van Gelder","year":"2008","unstructured":"van Gelder T, Silva HT, de Fijter JW, Budde K, Kuypers DR, Tyden G, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation. 2008;86:1043\u201351.","journal-title":"Transplantation"},{"key":"271_CR23","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s13318-021-00713-0","volume":"46","author":"J Sobiak","year":"2021","unstructured":"Sobiak J, Resztak M. A Systematic Review of Multiple Linear Regression-Based Limited Sampling Strategies for Mycophenolic Acid Area Under the Concentration-Time Curve Estimation. Eur J Drug Metab Pharmacokinet. 2021;46:721\u201342.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"271_CR24","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1046\/j.1365-2125.2003.01863.x","volume":"56","author":"B Shum","year":"2003","unstructured":"Shum B, Duffull SB, Taylor PJ, Tett SE. Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. Br J Clin Pharmacol. 2003;56:188\u201397.","journal-title":"Br J Clin Pharmacol"},{"key":"271_CR25","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s40262-017-0603-8","volume":"57","author":"H Colom","year":"2018","unstructured":"Colom H, Andreu F, van Gelder T, Hesselink DA, de Winter BCM, Bestard O, et al. Prediction of Free from Total Mycophenolic Acid Concentrations in Stable Renal Transplant Patients: A Population-Based Approach. Clin Pharmacokinet. 2018;57:877\u201393.","journal-title":"Clin Pharmacokinet"},{"key":"271_CR26","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3389\/fphar.2020.00340","volume":"11","author":"C Sheng","year":"2020","unstructured":"Sheng C, Zhao Q, Niu W, Qiu X, Zhang M, Jiao Z. Effect of Protein Binding on Exposure of Unbound and Total Mycophenolic Acid: A Population Pharmacokinetic Analysis in Chinese Adult Kidney Transplant Recipients. Front Pharmacol. 2020;11:340.","journal-title":"Front Pharmacol"},{"key":"271_CR27","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/FTD.0b013e3181a23f1a","volume":"31","author":"BC de Winter","year":"2009","unstructured":"de Winter BC, Neumann I, van Hest RM, van Gelder T, Mathot RA. Limited sampling strategies for therapeutic drug monitoring of mycophenolate mofetil therapy in patients with autoimmune disease. Ther Drug Monit. 2009;31:382\u201390.","journal-title":"Ther Drug Monit"},{"key":"271_CR28","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/FTD.0000000000000223","volume":"37","author":"P Luszczynska","year":"2015","unstructured":"Luszczynska P, Pawinski T. Therapeutic Drug Monitoring of Mycophenolic Acid in Lupus Nephritis: A Review of Current Literature. Ther Drug Monit. 2015;37:711\u20137.","journal-title":"Ther Drug Monit"},{"key":"271_CR29","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis."},{"key":"271_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31\u201341.","journal-title":"Nephron"},{"key":"271_CR31","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00228-018-2599-x","volume":"75","author":"P Luszczynska","year":"2019","unstructured":"Luszczynska P, Pawinski T, Kunicki PK, Durlik M, Augustyniak-Bartosik H, Hurkacz M. Pharmacokinetics of free and total mycophenolic acid in adult lupus nephritis patients-implications for therapeutic drug monitoring. Eur J Clin Pharmacol. 2019;75:371\u20139.","journal-title":"Eur J Clin Pharmacol"},{"key":"271_CR32","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"271_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-9485-1","volume-title":"Pharmacokinetic-Pharmacodynamic Modeling and Simulation","author":"PL Bonate","year":"2011","unstructured":"Bonate PL. Pharmacokinetic-Pharmacodynamic Modeling and Simulation. 2nd ed. New York: Springer; 2011.","edition":"2"},{"key":"271_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/9781118784860","volume-title":"Introduction to Population Pharmacokinetic\/Pharmacodynamic Analysis with Nonlinear Mixed Effects Models","author":"JS Owen","year":"2014","unstructured":"Owen JS, Fiedler-Kelly J. Introduction to Population Pharmacokinetic\/Pharmacodynamic Analysis with Nonlinear Mixed Effects Models. New York: John Wiley & Sons, Inc; 2014."},{"key":"271_CR35","unstructured":"Gabrielsson J, Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. 5th ed. Stockholm: Apotekarsocieteten; 2017."},{"key":"271_CR36","unstructured":"Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry: Population Pharmacokinetics. Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. 2022. https:\/\/www.fda.gov\/media\/128793\/download. Accessed 1 Oct 2022."},{"key":"271_CR37","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s11095-007-9361-x","volume":"24","author":"AC Hooker","year":"2007","unstructured":"Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res. 2007;24:2187\u201397.","journal-title":"Pharm Res"},{"key":"271_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","volume":"82","author":"MO Karlsson","year":"2007","unstructured":"Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82:17\u201320.","journal-title":"Clin Pharmacol Ther"},{"key":"271_CR39","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143\u201351.","journal-title":"AAPS J"},{"key":"271_CR40","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","volume":"43","author":"S Bergan","year":"2021","unstructured":"Bergan S, Brunet M, Hesselink DA, Johnson-Davis KL, Kunicki PK, Lemaitre F, et al. Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2021;43:150\u2013200.","journal-title":"Ther Drug Monit"},{"key":"271_CR41","doi-asserted-by":"publisher","first-page":"272","DOI":"10.5414\/CP201605","volume":"50","author":"B Punyawudho","year":"2012","unstructured":"Punyawudho B, Lertdumrongluk P, Somparn P, Kittanamongkolchai W, Traitanon O, Avihingsanon Y, et al. Population pharmacokinetics of mycophenolate mofetil in Thai lupus nephritis patients. Int J Clin Pharmacol Ther. 2012;50:272\u201380.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"271_CR42","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/01.tp.0000276936.14041.6c","volume":"84","author":"M Naesens","year":"2007","unstructured":"Naesens M, de Loor H, Vanrenterghem Y, Kuypers DR. The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. Transplantation. 2007;84:362\u201373.","journal-title":"Transplantation"},{"key":"271_CR43","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/FTD.0b013e31816337b7","volume":"30","author":"M Miura","year":"2008","unstructured":"Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Suzuki T, et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther Drug Monit. 2008;30:46\u201351.","journal-title":"Ther Drug Monit"},{"key":"271_CR44","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1067\/mcp.2000.111480","volume":"68","author":"M Morii","year":"2000","unstructured":"Morii M, Ueno K, Ogawa A, Kato R, Yoshimura H, Wada K, et al. Impairment of mycophenolate mofetil absorption by iron ion. Clin Pharmacol Ther. 2000;68:613\u201361.","journal-title":"Clin Pharmacol Ther"},{"key":"271_CR45","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1177\/0091270011412968","volume":"52","author":"MG Kees","year":"2012","unstructured":"Kees MG, Steinke T, Moritz S, Rupprecht K, Paulus EM, Kees F, et al. Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers. J Clin Pharmacol. 2012;52:1265\u20132127.","journal-title":"J Clin Pharmacol"},{"key":"271_CR46","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.3748\/wjg.v25.i22.2706","volume":"25","author":"G Bruno","year":"2019","unstructured":"Bruno G, Zaccari P, Rocco G, Scalese G, Panetta C, Porowska B, et al. Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified. World J Gastroenterol. 2019;25:2706\u201319.","journal-title":"World J Gastroenterol"},{"key":"271_CR47","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1046\/j.1365-2125.1996.03636.x","volume":"41","author":"R Bullingham","year":"1996","unstructured":"Bullingham R, Shah J, Goldblum R, Schiff M. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Br J Clin Pharmacol. 1996;41:513\u20136.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-022-00271-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-022-00271-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-022-00271-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T15:18:56Z","timestamp":1673623136000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-022-00271-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["271"],"URL":"https:\/\/doi.org\/10.1186\/s40780-022-00271-w","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"assertion":[{"value":"3 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was approved by the hospital ethics committee at Aichi Medical University (approval no. 2018-H258). Written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}